Back | Next |
home / stock / eq / eq message board
Subject | By | Source | When |
---|---|---|---|
$EQ great news | eastunder | investorshub | 04/20/2023 6:58:19 PM |
what do you make of this data? | MiamiGent | investorshub | 04/20/2023 2:42:20 AM |
I sold out a while ago to buy | jerseyboy | investorshub | 02/28/2021 5:14:44 AM |
I'm in this morning with a decent position. | jerseyboy | investorshub | 01/06/2021 5:57:53 PM |
znewcar1: EQ 41% v10,6M c6.18 f24,7M H6.39 | znewcar1 | investorshangout | 12/29/2020 9:23:22 PM |
But why? Why is it moving enough that | eastunder | investorshub | 12/29/2020 6:33:47 PM |
Nice bullish move today. | Actualfactual | investorshub | 12/29/2020 5:33:55 PM |
Live webcasts of both presentations will be available | eastunder | investorshub | 11/21/2020 10:46:54 PM |
Let me check for you. I'll see if | eastunder | investorshub | 11/21/2020 10:31:48 PM |
EQ is still just 1.5 x book value. | jimmy667 | investorshub | 11/20/2020 10:15:03 PM |
Looks like the investor conferences convinced a few | jimmy667 | investorshub | 11/20/2020 10:09:15 PM |
* * $EQ Video Chart 11-11-2020 * * | ClayTrader | investorshub | 11/11/2020 10:18:23 PM |
znewcar1: EQ 44% v36,1M c5.04 f24,2M H6.44 then sold off | znewcar1 | investorshangout | 11/11/2020 9:13:54 PM |
Emergency approval imminent | shurtha2000 | investorshub | 11/11/2020 5:50:12 PM |
Equillium to Present at Investor Conferences in November 2020 | eastunder | investorshub | 11/11/2020 5:32:01 PM |
Equillium Reports Third Quarter 2020 Financial Results and | eastunder | investorshub | 11/11/2020 5:25:04 PM |
EQ No but good alert, RN! | MiamiGent | investorshub | 11/10/2020 10:45:36 PM |
Any opinion on today's Q3-Filing updates. Don't find | RNsidersbuying | investorshub | 11/10/2020 10:40:03 PM |
Whats wrong with this pos?? | Roadtojourney | investorshub | 11/02/2020 9:09:13 PM |
Easy now children take it slow | Penny chatter | investorshub | 10/30/2020 4:05:36 PM |
News, Short Squeeze, Breakout and More Instantly...
Q2 ending cash, cash equivalents and short-term investments totaled approximately $33.3 million, an increase of approximately $1.0 million compared to the amount at the end of Q1 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutic...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it will be participating in the Leerink Partners Therapeutic Forum: I&I and Metabolism, as well as the Jone...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it expects to join the Russell Microcap Index at the conclusion of the 2024 Russell annual reconstitution, effe...